FDA Issues Warning on Type 2 Diabetes Drugs: Farxiga, Invokana, Jardiance

The US Food and Drug Administration (FDA) has issued a warning on type 2 diabetes drugs from several companies that may cause high levels of blood acid.

Type 2 DiabetesThe drugs include AstraZeneca‘s (NYSE:AZN) Farxiga, J&J‘s (NYSE:JNJ) Invokana and Lilly and Boehringer‘s (NYSE:LLY) Jardiance. These can cause ketoacidosis, a condition where the body produces high levels of acid called ketones.

The type 2 diabetes drugs are SGLT2 inhibitors that cause blood sugar to be secreted in the urine. The adverse effects from these substances may require hospitalization.

The FDA added that there have been at least 20 cases of acidosis resulting from the use of these drugs–all of which were emergency room visits or hospitalizations.

AZN stock is down 1.2% Friday. JNJ stock is up 0.3%. LLY is down 0.2%.

More From InvestorPlace


Article printed from InvestorPlace Media, https://investorplace.com/2015/05/type-2-diabetes-warning-farxiga/.

©2022 InvestorPlace Media, LLC